FR2227861B1 - - Google Patents

Info

Publication number
FR2227861B1
FR2227861B1 FR7316131A FR7316131A FR2227861B1 FR 2227861 B1 FR2227861 B1 FR 2227861B1 FR 7316131 A FR7316131 A FR 7316131A FR 7316131 A FR7316131 A FR 7316131A FR 2227861 B1 FR2227861 B1 FR 2227861B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7316131A
Other versions
FR2227861A1 (fr
Inventor
Edgar Hans Relyveld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bpifrance Financement SA
Original Assignee
Agence National de Valorisation de la Recherche ANVAR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agence National de Valorisation de la Recherche ANVAR filed Critical Agence National de Valorisation de la Recherche ANVAR
Priority to FR7316131A priority Critical patent/FR2227861B1/fr
Priority to US05/465,712 priority patent/US3983229A/en
Priority to JP4887374A priority patent/JPS57844B2/ja
Priority to DE2421083A priority patent/DE2421083C2/de
Priority to GB1958474A priority patent/GB1473541A/en
Priority to CH606574A priority patent/CH608962A5/xx
Priority to NL7406013A priority patent/NL188504C/xx
Priority to OA55194A priority patent/OA04704A/fr
Publication of FR2227861A1 publication Critical patent/FR2227861A1/fr
Application granted granted Critical
Publication of FR2227861B1 publication Critical patent/FR2227861B1/fr
Priority to US05/704,706 priority patent/US4075321A/en
Priority to US05/704,255 priority patent/US4070454A/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/125Picornaviridae, e.g. calicivirus
    • A61K39/13Poliovirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/05Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/099Bordetella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/125Picornaviridae, e.g. calicivirus
    • A61K39/135Foot- and mouth-disease virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/38Antigens from snakes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32111Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32111Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32151Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32611Poliovirus
    • C12N2770/32634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806Antigenic peptides or proteins
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82Proteins from microorganisms
    • Y10S530/825Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR7316131A 1973-05-04 1973-05-04 Expired FR2227861B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR7316131A FR2227861B1 (fr) 1973-05-04 1973-05-04
US05/465,712 US3983229A (en) 1973-05-04 1974-04-30 Vaccines, the process for preparing the same and the applications thereof
DE2421083A DE2421083C2 (de) 1973-05-04 1974-05-02 Impfstoffe und Verfahren zu ihrer Herstellung
JP4887374A JPS57844B2 (fr) 1973-05-04 1974-05-02
GB1958474A GB1473541A (en) 1973-05-04 1974-05-03 Vaccines processes for preparing the same applications thereof and hyperimmune sera prepared therefrom
CH606574A CH608962A5 (fr) 1973-05-04 1974-05-03
NL7406013A NL188504C (nl) 1973-05-04 1974-05-03 Werkwijze voor het bereiden van vaccins tegen difterie, tetanus, kinkhoest en poliomyelitis.
OA55194A OA04704A (fr) 1973-05-04 1974-05-03 Procédé de préparation de nouveaux vaccins.
US05/704,706 US4075321A (en) 1973-05-04 1976-07-12 Vaccines, the process for preparing the same and the applications thereof
US05/704,255 US4070454A (en) 1973-05-04 1976-07-12 Vaccines, the process for preparing the same and the applications thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7316131A FR2227861B1 (fr) 1973-05-04 1973-05-04

Publications (2)

Publication Number Publication Date
FR2227861A1 FR2227861A1 (fr) 1974-11-29
FR2227861B1 true FR2227861B1 (fr) 1976-07-02

Family

ID=9118826

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7316131A Expired FR2227861B1 (fr) 1973-05-04 1973-05-04

Country Status (8)

Country Link
US (1) US3983229A (fr)
JP (1) JPS57844B2 (fr)
CH (1) CH608962A5 (fr)
DE (1) DE2421083C2 (fr)
FR (1) FR2227861B1 (fr)
GB (1) GB1473541A (fr)
NL (1) NL188504C (fr)
OA (1) OA04704A (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4070454A (en) * 1973-05-04 1978-01-24 Agence Nationale De Valorisation De La Recherche (Anvar) Vaccines, the process for preparing the same and the applications thereof
US4180562A (en) * 1973-05-08 1979-12-25 Northwestern University Glutaraldehyde polymerized ragweed antigen E preparation for treatment of allergic patients sensitive to ragweed pollen
CA1085293A (fr) * 1976-02-05 1980-09-09 Yuzuru Homma Anatoxines derivees de la protease et de l'elastase de pseudomonas aeruginosa et procede de production
JPS5296729A (en) * 1976-02-05 1977-08-13 Shionogi & Co Ltd Mixed vaccin for cyanomycosis
JPS52158755U (fr) * 1976-05-26 1977-12-02
GB1581776A (en) * 1976-08-18 1980-12-17 Smith Kline Rit Vaccines against oedema disease of piglets
US4357272A (en) * 1978-03-22 1982-11-02 The South African Inventions Development Corporation Recovering purified antibodies from egg yolk
IL58009A (en) * 1978-08-14 1982-11-30 Sterling Drug Inc Process and compositions comprising glutaric acid for neutralizing or destroying viruses
US4234569A (en) * 1978-10-04 1980-11-18 The Johns Hopkins University Production of aldehyde-treated allergen-containing substances
US4264588A (en) * 1979-05-10 1981-04-28 The Charles River Breeding Laboratories, Inc. Vaccine for Clostridium perfringens type E enterotoxemia of rabbits
US4269764A (en) * 1979-08-02 1981-05-26 Roy Patterson Preparation for treatment of allergic patients sensitive to ragweed pollen
EP0043272B1 (fr) * 1980-07-01 1984-06-13 National Research Development Corporation Production d'antigènes viraux
US4328208A (en) * 1981-05-20 1982-05-04 Kurbanov Ildus A Vaccine against chlamydous infections of farm animals
US4465665A (en) * 1982-03-04 1984-08-14 Smithkline-Rit Detoxified E. coli neurotoxin, preparation thereof and immunological preparations containing it
EP0089854B1 (fr) * 1982-03-24 1988-12-07 The University Of Birmingham Vaccin contre des virus à ADN
HU188847B (en) * 1983-02-22 1986-05-28 Human Oltoanyagtermeloe Es Kutato Intezet,Hu Process for producing liophylized combined vaccines
JPS59206316A (ja) * 1983-05-11 1984-11-22 Kaken Pharmaceut Co Ltd インシユリン分泌増強活性物質誘導体およびその製法
US4473495A (en) * 1983-07-28 1984-09-25 Northwestern University Albumin-solubilized hymenoptera venoms for vaccine use
AT391080B (de) * 1986-06-24 1990-08-10 Immuno Ag Verfahren zur herstellung von gegen pseudomonas aeruginosa infektionen wirksamen praeparationen
US5237053A (en) * 1986-06-24 1993-08-17 Immuno Aktiengesellschaft Preparation active against Pseudomonas aeruginosa infections and methods of producing them
US4841023A (en) * 1986-06-25 1989-06-20 New York Blood Center, Inc. Inactivation of viruses in labile protein-containing compositions using fatty acids
US4888169A (en) * 1986-10-14 1989-12-19 Norden Laboratories, Inc. Bordetella Bronchiseptica vaccine
US5292869A (en) * 1989-04-27 1994-03-08 The Board Of Governors Of The University Method for isolating and purifying transferrin and lactoferrin receptor proteins from bacteria and the preparation of vaccines containing the same
US5578308A (en) * 1990-02-12 1996-11-26 Capiau; Carine Glutaraldehyde and formalin detoxified bordetella toxin vaccine
EP0814834B2 (fr) 1995-03-08 2009-03-18 Neovacs Immunogenes denues de toxicite derivant d'une proteine de regulation retrovirale, anticorps diriges contre ces immunogenes, procede pour leur preparation et compositions pharmaceutiques les renfermant
US20020068090A1 (en) * 1999-02-03 2002-06-06 Bell Steve J. D. Calcium phosphate particles as mucosal adjuvants
US20020054914A1 (en) * 1999-02-03 2002-05-09 Tulin Morcol Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
ATE276199T1 (de) * 1999-02-03 2004-10-15 Biosante Pharmaceuticals Inc Methoden zur herstellung von therapeutische kalzium-phosphat partikeln
US20040258763A1 (en) * 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
JP2002063917A (ja) * 2000-08-18 2002-02-28 Sony Corp 電気化学デバイス及びその使用方法
DK1450855T3 (da) * 2001-05-23 2010-01-11 Duotol Ab Undertrykkelse af allergiske reaktioner ved hjælp af transdermal indgivelse af allergener i forbindelse med eller konjugeret til toxin-underenheder eller fragmenter deraf
US20030185892A1 (en) * 2001-08-17 2003-10-02 Bell Steve J. D. Intraocular delivery compositions and methods
NZ553776A (en) * 2004-09-22 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.
US20090041812A1 (en) * 2004-11-01 2009-02-12 Bell Steve J D Therapeutic Calcium Phosphate Particles in Use for Aesthetic of Cosmetic Medicine, and Methods of Manufacture and Use
CN114129719A (zh) * 2021-12-03 2022-03-04 张公义 广谱疫苗的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135662A (en) * 1961-01-05 1964-06-02 Burroughs Wellcome Co Diphtheria toxoid preparation and its production
FR1604134A (fr) * 1967-09-26 1971-07-12
GB1282163A (en) * 1969-08-06 1972-07-19 Beecham Group Ltd Modified allergens and a process for their preparation
US3761585A (en) * 1971-04-05 1973-09-25 Beecham Group Ltd Vaccines containing modified allergenic material

Also Published As

Publication number Publication date
JPS5029737A (fr) 1975-03-25
US3983229A (en) 1976-09-28
CH608962A5 (fr) 1979-02-15
OA04704A (fr) 1980-08-31
DE2421083C2 (de) 1987-05-07
DE2421083A1 (de) 1974-11-21
NL188504C (nl) 1992-07-16
GB1473541A (en) 1977-05-11
NL7406013A (fr) 1974-11-06
JPS57844B2 (fr) 1982-01-08
NL188504B (nl) 1992-02-17
FR2227861A1 (fr) 1974-11-29

Similar Documents

Publication Publication Date Title
AU476761B2 (fr)
AR201231Q (fr)
FR2227861B1 (fr)
AU474593B2 (fr)
AU474511B2 (fr)
AU474838B2 (fr)
AU476714B2 (fr)
AU472848B2 (fr)
AU476696B2 (fr)
AU480131B2 (fr)
AU477823B2 (fr)
AU476873B1 (fr)
AR210729A1 (fr)
AU447540B2 (fr)
AR200885A1 (fr)
AU471461B2 (fr)
AU477824B2 (fr)
AU461342B2 (fr)
AU1891376A (fr)
CH564270A5 (fr)
BG20696A1 (fr)
CH564195A5 (fr)
CH567203A5 (fr)
CH564173A5 (fr)
CH567288A5 (fr)

Legal Events

Date Code Title Description
TP Transmission of property
TP Transmission of property